sur ABIVAX (EPA:ABVX)
Abivax Responds to Short Seller Report by Scorpion Capital
On November 20, 2026, Abivax, a clinical-stage biotechnology company, issued a statement disputing a recent report by Scorpion Capital. The Paris-based firm, focused on immune response therapies for chronic inflammatory diseases, declares the report as factually inaccurate and misleading.
Abivax emphasizes the integrity of its clinical development, specifically its Phase 3 ABTECT trials, and plans to proceed with a U.S. FDA NDA filing by year-end. The company suggests Scorpion Capital's disclosed short position in Abivax raises questions about the report's neutrality due to their financial interest in a declining share price.
Further updates from Abivax regarding this matter are anticipated as the company continues to review the report's details.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX